Entity

Time filter

Source Type


Tamiya M.,Prefectural Medical Center for Respiratory and Allergic Diseases | Kobayashi M.,Prefectural Medical Center for Respiratory and Allergic Diseases | Morimura O.,Prefectural Medical Center for Respiratory and Allergic Diseases | Yasue T.,Prefectural Medical Center for Respiratory and Allergic Diseases | And 10 more authors.
Clinical Lung Cancer | Year: 2013

Introduction: Lung cancer is the leading cause of cancer-related death. Many patients with lung cancer are in its advanced stages at the time of diagnosis. The 5-year survival rate for lung cancer is 10% to 20%, and the prognosis for patients with lung cancer is still poor. The crosslinked N-terminal telopeptide of type I collagen (NTx) is a metabolite of type I collagen, the main constituent of bone matrix. Patients and Methods: We measured serum NTx levels in patients who underwent staging during hospitalization for the initial treatment of lung cancer in our department. We examined whether serum NTx levels would be relevant to the prognosis of non-small-cell lung cancer (NSCLC). Results: This study included 176 patients with lung cancer (125 men and 51 women), including 109 with adenocarcinoma, 53 with squamous cell carcinoma, 6 with large-cell carcinoma, and 8 with other cancer types. Univariate and multivariate analysis using the Cox proportional hazards model revealed a particularly close association between sex, performance status, disease stage, and serum NTx levels and overall survival (OS). A median OS of 368 days was observed for patients with a serum NTx level < 22 nmol BCE/L, which was significantly longer than the 197 days for patients with a serum NTx level ≥ 22 nmol BCE/L (hazard ratio [HR], 2.02; 95% confidence interval [CI], 1.36-2.99; log-rank P =.00037). Conclusions: We have revealed that a high serum NTx level (> 22 nmol BCE/L) appears to be a risk factor for a reduction in OS in patients with NSCLC. © 2013 Elsevier Inc. All rights reserved.


Tamiya A.,Kinki chuo Chest Medical Center | Tamiya M.,Prefectural Medical Center for Respiratory and Allergic Diseases | Shiroyama T.,Prefectural Medical Center for Respiratory and Allergic Diseases | Kanazu M.,Kinki chuo Chest Medical Center | And 11 more authors.
Annals of Oncology | Year: 2013

Background: This study was designed to determine the recommended dose of carboplatin-pemetrexed in elderly (≥75 years old), chemotherapy-naive patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC). Patients and methods: Patients received escalated doses of carboplatin and pemetrexed every 3 weeks for four cycles. Patients with an objective response and stable disease continued pemetrexed therapy until disease progression or unacceptable toxicity was observed. Results: The combination of carboplatin at an area under the concentration-time curve (AUC) of 5, and 500 mg/m. 2 pemetrexed, was determined to be the recommended dose for elderly patients with advanced nonsquamous NSCLC. Of 17 patients, 10 received a median of five cycles of pemetrexed maintenance therapy without unexpected or cumulative toxic effects. The study had an overall response rate of 47.1%. The median progression-free survival time was 142 days (95% confidence interval [CI] 68-216 days) and the median overall survival time was 461 days (95% CI 168-754 days). Conclusions: This combination was a tolerable and effective regimen, and recommended dose (RD) was carboplatin [area under the curve (AUC) of 5]/pemetrexed (500 mg/m. 2) every 3 weeks, in chemotherapy-naïve, elderly (≥75 years old) patients with advanced nonsquamous NSCLC. © The Author 2012.


Shiroyama T.,Prefectural Medical Center for Respiratory and Allergic Diseases | Okamoto N.,Prefectural Medical Center for Respiratory and Allergic Diseases | Tamiya M.,Prefectural Medical Center for Respiratory and Allergic Diseases | Hamaguchi M.,Prefectural Medical Center for Respiratory and Allergic Diseases | And 7 more authors.
Internal Medicine | Year: 2016

A 72-year-old man with salivary gland cancer and multiple pulmonary metastases suffering from intractable pneumothorax was transferred to our institution; he was inoperable because of a low pulmonary function. A chest tube had been placed more than a month prior to this admission. A digital drainage system was used for 24-h monitoring of air leaks (Thopaz®). Using the Thopaz® system, we performed endoscopic bronchial occlusion using an endobronchial Watanabe spigot (EWS) to reduce air leaks. Finally, the air leaks ceased, and the chest tube was removed five days after EWS placement. We herein report a case of persistent pneumothorax that was successfully treated by endoscopic bronchial EWS placement with the aid of a Thopaz® system. © 2016 The Japanese Society of Internal Medicine.

Discover hidden collaborations